XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]      
Company's mission description The Company’s mission is to cure Duchenne muscular dystrophy (“Duchenne”), a genetic muscle-wasting disease predominantly affecting boys.    
Medicine description In March 2022, the Company reported two-year interim safety and efficacy data from the first three patients treated with SGT-001 in the 2E14 vg/kg dose cohort of IGNITE DMD, which results suggested durable benefit compared with natural history trajectories 24 months post-administration of SGT-001 across functional, pulmonary and patient reported outcome measures. In addition, no new drug-related safety findings have been identified in patients treated with SGT-001 in IGNITE DMD in post-dosing periods of 90 days to approximately four years. In April 2022, the Company announced that it had concluded enrollment in IGNITE DMD.    
Net loss $ 25,328 $ 16,900  
Accumulated deficit 502,085   $ 476,757
Net cash used in operating activities 27,190 $ 21,366  
Cash, cash equivalents and available-for-sale securities $ 180,050